Scotland has become the seventeenth country in Europe to agree to reimburse Elfabrio (pegunigalsidase alfa), Chiesi’s treatment for Fabry disease that was rejected by France’s health technology assessment (HTA) body.
The Scottish Medicines Consortium announced its decision to fund the enzyme replacement therapy this month, meaning that the product will soon be available on a routine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?